Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov-Dec;7(11-12):E812-6.
doi: 10.5489/cuaj.363.

Transurethral resection and degeneration of bladder tumour

Aihua Li  1 , Wei Fang  1 , Feng Zhang  1 , Weiwu Li  1 , Honghai Lu  1 , Sikuan Liu  1 , Hui Wang  1 , Binghui Zhang  1
Affiliations

Transurethral resection and degeneration of bladder tumour

Aihua Li et al. Can Urol Assoc J. 2013 Nov-Dec.

Abstract

Introduction: We evaluate the efficacy and safety of transurethral resection and degeneration of bladder tumour (TURD-Bt).

Methods: In total, 56 patients with bladder tumour were treated by TURD-Bt. The results in these patients were compared with 32 patients treated by current transurethral resection of bladder tumour (TUR-Bt). Patients with or without disease progressive factors were respectively compared between the 2 groups. The factors included recurrent tumour, multiple tumours, tumour ≥3 cm in diameter, clinical stage T2, histological grade 3, adenocarcinoma, and ureteral obstruction or hydronephrosis.

Results: Follow-up time was 48.55 ± 23.74 months in TURD-Bt group and 56.28 ± 17.61 months in the TUR-Bt group (p > 0.05). In patients without progressive factors, no tumour recurrence was found and overall survival was 14 (100%) in the TURD-Bt group; 3 (37.50%) patients had recurrence and overall survival was 5 (62.5%) in the TUR-Bt group. In patients with progressive factors, 8 (19.05%) patients had tumour recurrence, overall survival was 32 (76.19%) and cancer death was 3 (7.14%) in TURD-Bt group; 18 (75.00%) patients had tumour recurrence (p < 0.05), overall survival was 12 (50.00%) (p < 0.01) and cancer death was 8 (33.33%) (p < 0.05) in TUR-Bt group. No significant complication was found in TURD-Bt group.

Conclusion: This study suggests that complete resection and degeneration of bladder tumour can be expected by TURD-Bt. The surgical procedure is safe and efficacious, and could be predictable and controllable before and during surgery. We would conclude that for bladder cancers without lymph node metastasis and distal metastasis, TURD-Bt could be performed to replace radical TUR-Bt and preserve the bladder.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The surgical management to the bladder tumour in different anatomical layers.
Fig. 2.
Fig. 2.
The anatomical layers of resected, vaporized and coagulating degenerated portion were located in bladder wall.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Leibovici D, Kassouf W, Pisters LL, et al. Organ preservation for muscle-invasive bladder cancer by trans-urethral resection. Urol. 2007;70:473–6. doi: 10.1016/j.urology.2007.05.007. - DOI - PubMed
    1. Merseburger AS, Kuczyk MA. The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery. Curr Opin Urol. 2007;17:358–62. doi: 10.1097/MOU.0b013e3282c4afa0. - DOI - PubMed
    1. Gallagher DJ, Milowsky MI. Bladder cancer. Curr Treat Options Oncol. 2009;10:205–15. doi: 10.1007/s11864-009-0112-6. - DOI - PubMed
    1. Kaufman DS. Challenges in the treatment of bladder cancer. Ann Oncol. 2006;17(Suppl 5):v106–12. doi: 10.1093/annonc/mdj963. - DOI - PubMed
    1. George L, Bladou F, Bardou VRJ, et al. Clinical outcom in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology. 2004;64:488–93. doi: 10.1016/j.urology.2004.04.088. - DOI - PubMed

LinkOut - more resources